Medicare Enrolled
Dr. Nancy Rubin, D.O.
Hematology & Oncology · Monterey, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rubin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rubin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rubin
Dr. Nancy Rubin is a hematology & oncology specialist in Monterey, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rubin performed 172,821 Medicare services across 3,927 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rubin received a total of $686 from 20 pharmaceutical and/or device companies across 30 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rubin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in CA
$686 industry payments
Medicare Practice Summary
Medicare Utilization ↗172,821
Medicare services
Top 3% in CA for hematology & oncology
3,927
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~9,096 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim-ayow biosimilar injection, 1 microgram An injection of the biosimilar medication filgrastim-ayow (Releuko) at a dose of 1 microgram. |
26,940 | $0 | $2 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
22,500 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 21,480 | $18 | $59 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
18,600 | $2 | $8 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
13,860 | $37 | $121 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
13,380 | $0 | $1 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
11,220 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 11,205 | $43 | $139 |
| Paclitaxel chemotherapy injection | 6,943 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,850 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
5,550 | $6 | $22 |
| Injection, fulvestrant, 25 mg | 2,270 | $8 | $28 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,070 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,651 | $102 | $347 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,595 | $8 | $33 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,587 | $8 | $32 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,050 | $1 | $3 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
744 | $12 | $39 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
380 | $25 | $82 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
364 | $115 | $376 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
355 | $71 | $246 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
335 | $142 | $485 |
| Chronic care management, first 30 minutes This service covers the initial 30 minutes of care coordination for patients with two or more chronic conditions. It is provided personally by a healthcare professional each calendar month. |
259 | $67 | $227 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
243 | $28 | $101 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
216 | $104 | $341 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
183 | $64 | $209 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
181 | $2 | $7 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
175 | $10 | $25 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
163 | $54 | $184 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
117 | $14 | $44 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
115 | $18 | $66 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
115 | $5 | $21 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
109 | $24 | $80 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
106 | $98 | $314 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
89 | $1 | $3 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
85 | $57 | $185 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
82 | $0 | $33 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 68 | $132 | $427 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
66 | $17 | $59 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
59 | $11 | $39 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
47 | $21 | $74 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
45 | $1 | $5 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
41 | $3 | $16 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
36 | $2 | $7 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
34 | $65 | $246 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
33 | $17 | $56 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
32 | $98 | $347 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
31 | $29 | $75 |
| New patient office visit, complex (60-74 min) | 30 | $168 | $593 |
| Virtual check-in for established patient A brief communication service provided by a qualified healthcare professional to an established patient via technology, such as a virtual check-in. |
20 | $12 | $38 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
19 | $49 | $158 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
18 | $16 | $42 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 13 | $20 | $53 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
13 | $29 | $93 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $144 | $458 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
12 | $13 | $26 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
12 | $6 | $24 |
| Chronic care management services Comprehensive assessment and care planning for patients requiring ongoing chronic care management. |
12 | $44 | $168 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
20.2% high complexity
76.0% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$686
Total received (2018-2024)
Avg $114/year across 6 years
Bottom 29% in CA for hematology & oncology
20
Companies
30
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$661 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$25 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$42
2023
$192
2022
$127
2021
$133
2019
$61
2018
$131
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$26
E.R. Squibb & Sons, L.L.C.
$16
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$144
Takeda Pharmaceuticals U.S.A., Inc.
$75
Daiichi Sankyo Inc.
$56
TESARO, Inc.
$44
Lilly USA, LLC
$42
PFIZER INC.
$39
Incyte Corporation
$27
CTI BioPharma Corp.
$27
AbbVie Inc.
$25
G1 Therapeutics, Inc.
$24
AbbVie, Inc.
$23
EMD Serono, Inc.
$22
Sobi, Inc
$21
GlaxoSmithKline, LLC.
$20
Clovis Oncology, Inc.
$20
Janssen Biotech, Inc.
$19
Novocure Inc.
$18
Genentech USA, Inc.
$14
Agios Pharmaceuticals, Inc.
$14
Gilead Sciences, Inc.
$12
Top 3 companies account for 40.1% of all-time payments
Associated products mentioned in payments ›
Alecensa · Bavencio · COSELA · DOPTELET · ELIQUIS · ELREXFIO · ERLEADA · Enhertu · IBRANCE · IDHIFA · JAKAFI · NINLARO · OPDIVO · OPTUNE LUA (NOVOTTF-200T) · Rubraca · VENCLEXTA · VERZENIO · Venclexta · Vonjo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
12
Per 100K population
2.8
County median income
$94,486
Nearest hospital
COMMUNITY HOSPITAL OF THE MONTEREY PENINSULA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rubin is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rubin experienced with filgrastim-ayow biosimilar injection, 1 microgram?
Based on Medicare claims data, Dr. Rubin performed 26,940 filgrastim-ayow biosimilar injection, 1 microgram services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rubin receive payments from pharmaceutical companies?
Yes. Dr. Rubin received a total of $686 from 20 companies across 30 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rubin's costs compare to other hematology & oncology specialists in Monterey?
Dr. Rubin's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rubin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Monterey
Browse hematology & oncology specialists in Monterey ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology